Scientific Advisory Board formed with internationally recognized liver and biliary tract cancer physicians to support the advancement of solid tumor pipeline programs; Elevar plan ...

Expression of Trop2, Nectin-4, and FOLR1 cell surface markers in biliary tract cancers: Is it time to repurpose drugs? This is an ASCO Meeting Abstract from the 2025 ASCO Gastrointestinal Cancers ...

Clinical landscape of cell free DNA alterations in patients with advanced biliary tract cancer treated with targeted therapies.

Methods: From August 2013 to June 2022, CHB patients at Hebei Medical University Third Hospital (Hebei, China) were recruited. Intrahepatic cccDNA was quantified and its association with liver ...

Hepatocellular carcinoma is the most common form of liver cancer. It can begin as a single tumor or multiple small tumors throughout the liver. Intrahepatic Cholangiocarcinoma A cancerous tumor in the ...

Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor ...

TYRA is also developing TYRA-200, an oral, investigational, FGFR1/2/3 inhibitor, in the SURF201 study for metastatic intrahepatic cholangiocarcinoma, and TYRA-430, an oral, investigational FGFR4/3 ...

Patients diagnosed with the three main types of bile duct cancer (intrahepatic, perihilar or distal cholangiocarcinoma) or with cancer of the gallbladder may be eligible for participation in the ...

Patients diagnosed with the three main types of bile duct cancer (intrahepatic, perihilar or distal cholangiocarcinoma) or with cancer of the gallbladder may be eligible for participation in the SAFIR ...

1 Department of Hepatopancreatobiliary Surgery, The Affiliated People’s Hospital of Ningbo University, Ningbo, China 2 Health Science Center, Ningbo University, Ningbo, China Intrahepatic ...